Kaisa Kivistö1,2, Sarimari Tupola3,4, Satu Kivitie-Kallio5,6. 1. Social Pediatrics Outpatient Clinic, Hospital for Children and Adolescents, Helsinki University Central Hospital, HUS, P.O. Box 280, FI-00029, Helsinki, Finland. kaisa.kivisto@helsinki.fi. 2. University of Helsinki, Helsinki, Finland. kaisa.kivisto@helsinki.fi. 3. Social Pediatrics Outpatient Clinic, Hospital for Children and Adolescents, Helsinki University Central Hospital, HUS, P.O. Box 280, FI-00029, Helsinki, Finland. sarimari.tupola@hus.fi. 4. University of Helsinki, Helsinki, Finland. sarimari.tupola@hus.fi. 5. Social Pediatrics Outpatient Clinic, Hospital for Children and Adolescents, Helsinki University Central Hospital, HUS, P.O. Box 280, FI-00029, Helsinki, Finland. satu.kivitie-kallio@hus.fi. 6. University of Helsinki, Helsinki, Finland. satu.kivitie-kallio@hus.fi.
Abstract
UNLABELLED: Our prospective study is among the first attempts to examine the health of prenatally buprenorphine-exposed children after neonatal age and to determine the types of child maltreatment in this patient group. The study population included 102 children (61/41 Caucasian males/females) who had a positive urine screen for buprenorphine as a newborn. In addition to buprenorphine, the children were also prenatally exposed to other substances. The data were collected by pediatricians in follow-up visits until 3 years of age and from medical records. Ten prenatally buprenorphine-exposed children (10 %) had some birth defect. The study children had slightly more major anomalies than newborns on average in Finland (3.4 %). Eye disorders (nystagmus, opticus atrophy, and strabismus) occurred in 11 % of children. One child was diagnosed with hepatitis C transmission. One female died of sudden infant death syndrome (SIDS), and one male died of congenital heart disease. Pediatricians submitted altogether 70 reports to child welfare services of suspected maltreatment. Of these reports, 45 (64 %) involved medical neglect. Physical abuse was suspected in four reports. CONCLUSION: We suggest that prenatally buprenorphine-exposed children have several types of problems with their health at toddler age and that they are susceptible to child maltreatment, especially to medical neglect.
UNLABELLED: Our prospective study is among the first attempts to examine the health of prenatally buprenorphine-exposed children after neonatal age and to determine the types of child maltreatment in this patient group. The study population included 102 children (61/41 Caucasian males/females) who had a positive urine screen for buprenorphine as a newborn. In addition to buprenorphine, the children were also prenatally exposed to other substances. The data were collected by pediatricians in follow-up visits until 3 years of age and from medical records. Ten prenatally buprenorphine-exposed children (10 %) had some birth defect. The study children had slightly more major anomalies than newborns on average in Finland (3.4 %). Eye disorders (nystagmus, opticus atrophy, and strabismus) occurred in 11 % of children. One child was diagnosed with hepatitis C transmission. One female died of sudden infant death syndrome (SIDS), and one male died of congenital heart disease. Pediatricians submitted altogether 70 reports to child welfare services of suspected maltreatment. Of these reports, 45 (64 %) involved medical neglect. Physical abuse was suspected in four reports. CONCLUSION: We suggest that prenatally buprenorphine-exposed children have several types of problems with their health at toddler age and that they are susceptible to child maltreatment, especially to medical neglect.
Authors: E A Mitchell; P G Tuohy; J M Brunt; J M Thompson; M S Clements; A W Stewart; R P Ford; B J Taylor Journal: Pediatrics Date: 1997-11 Impact factor: 7.124
Authors: H J de Koning; J G de Ridder-Sluiter; H M E van Agt; C M M Reep-van den Bergh; H A van der Stege; I J Korfage; J J Polder; P J van der Maas Journal: J Med Screen Date: 2004 Impact factor: 2.136
Authors: Eric Rubenstein; Jessica C Young; Lisa A Croen; Carolyn DiGuiseppi; Nicole F Dowling; Li-Ching Lee; Laura Schieve; Lisa D Wiggins; Julie Daniels Journal: J Autism Dev Disord Date: 2019-01
Authors: Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori Journal: Drug Saf Date: 2016-10 Impact factor: 5.606
Authors: Jennifer N Lind; Julia D Interrante; Elizabeth C Ailes; Suzanne M Gilboa; Sara Khan; Meghan T Frey; April L Dawson; Margaret A Honein; Nicole F Dowling; Hilda Razzaghi; Andreea A Creanga; Cheryl S Broussard Journal: Pediatrics Date: 2017-06 Impact factor: 7.124
Authors: Stacey L Klaman; Krystyna Isaacs; Anne Leopold; Joseph Perpich; Susan Hayashi; Jeff Vender; Melinda Campopiano; Hendrée E Jones Journal: J Addict Med Date: 2017 May/Jun Impact factor: 3.702